[目的]探讨多西他赛联合奈达铂同步放化疗治疗中晚期宫颈癌的临床疗效。[方法]96例中晚期宫颈癌患者分为单纯放射治疗组(48例)和同步放化疗组(48例,给予多西他赛联合奈达铂化学治疗,同时给予放射治疗),对两组病例的近期疗效、局部复发率、远处转移率、1年生存率、2年生存率和不良反应进行对比分析。[结果]单纯放射治疗组和同步放化疗组治疗的有效率分别为72.9%和95.8%,两组比较差异有统计学意义(χ2=9.56,P<0.05);同步放化疗组1年生存率97.9%、2年生存率93.8%明显高于单纯放疗组83.3%和79.2%,两组比较差异有统计学意义(χ2=4.41,χ2=4.36,P<0.05);同步放化疗组局部复发率(4.2%)及远处转移率(4.2%)明显低于单纯放疗组25.0%和20.8%(χ2=8.36,χ2=6.10,P<0.05);同步放化疗组和单纯放射治疗组的近期不良反应均以骨髓抑制为主,前者高于后者,差异有统计学意义(P<0.05),但患者均能耐受。[结论]应用多西他赛联合奈达铂同步放化疗方案治疗中晚期宫颈癌患者临床疗效确切,患者耐受性较好,能够降低宫颈癌局部复发及远处转移率,明显改善患者生存率。 [Objective] To investigate the clinical efficacy of docetaxel plus nedaplatin in concurrent chemotherapy for advanced cervical cancer. [Methods] Ninety-six patients with advanced cervical cancer were divided into radiotherapy group (48 cases) and concurrent chemoradiotherapy group (48 cases, docetaxel combined with nedaplatin chemotherapy, while given radiotherapy), two groups The recent curative effect, local recurrence rate, distant metastasis rate, 1-year survival rate, 2-year survival rate and adverse reactions were compared. [Results] The effective rates of radiotherapy alone group and concurrent radiochemotherapy group were 72.9% and 95.8% respectively, with significant difference between the two groups (χ2 = 9.56, P <0.05). The 1-year survival rate 97.9%. The 2-year survival rate was 93.8%, which was significantly higher than 83.3% and 79.2% in radiotherapy alone group (χ2 = 4.41, χ2 = 4.36, P <0.05) (4.2%) and distant metastasis (4.2%) were significantly lower than 25.0% and 20.8% (χ2 = 8.36, χ2 = 6.10, P <0.05) in radiotherapy alone group; The response was mainly bone marrow suppression, the former is higher than the latter, the difference was statistically significant (P <0.05), but patients were able to tolerate. [Conclusion] The docetaxel combined with nedaplatin concurrent chemoradiotherapy regimen in the treatment of advanced cervical cancer patients with clinical curative effect, the patient is better, can reduce the local recurrence and distant metastasis of cervical cancer, significantly improve the survival rate .